ORM稀土元素勘探作业紧锣密鼓多项目显利好

2013-03-29 14:30:37 来源：澳华财经在线 编辑：杨欣

ACB News《澳华财经在线》报道：中资控股澳交所上市企业Orion Metals（ASX：ORM）27日向市场发布季度报告披露截至2月28日该公司的运营情况和财务报告。公告显示，截至2月28日该公司持有现金229.9万澳元。

截至目前该公司已获得西澳矿产石油厅颁发的四块新矿权租地的勘探许可证，这四块租地位于西澳中部的塔纳米沙漠区，面积达475平凡公里，为该公司旗下Killi Killi稀土元素金矿项目的一部分，隶属于该公司的全资子公司Rich Resources Investments。Orion已委托地质咨询公司Salva Resources对Killi Killi项目进行评估。

Orion将于2012—13季度雨季过后重启Broughton Creek稀土元素铀矿项目现场作业。在获得矿权租地勘探许可证后，Orion将开始Fulford&Bonnor Creeks稀土元素项目（由三块矿权租地组成）现场作业。

公告显示，Orion持有Ultimate Resources公司43.9%的股份，后者已获得位于韩国的Eorea San和Hongchon稀土元素项目的采矿权。该公司正在评估多个潜在收购目标项目欲增加其矿产资产。

Orion Metals主要从事稀土元素及金矿勘探，在西澳及昆州东北铀矿区附近拥有多个项目，西澳的Killi Killi项目为其旗舰资产。北京琮霖集团和琮霖集团董事长岳琮霖先生共持有该公司70.03%的股份。

当日该股盘中最高触及0.079澳元，收于0.078澳元，成交量为25 000股。进入2013年以来该股基本稳定于0.075澳元。

Tags: ORM OrionMetals 西澳昆州稀土金矿铀矿北京琮霖集团澳洲股市 

相关阅读

: 【异动股】碳酸锂价格回升带来扩张契机 Patagonia Lithium (ASX:PL3) Formentera锂卤水项目钻探备受关注年内飙升逾2倍

Patagonia Lithium Ltd (ASX股票代码:PL3)位于阿根廷北部“锂三角”地带的Formentera/Cilon锂卤水项目钻探进展备受市场关注，今年以来PL3创出233.33%涨幅，尽管并无消息披露，周三再度飙涨28.57%，周涨幅扩大至63.64%。

: From Demonstration to Commercialisation: Calix’s Industrial Decarbonisation Platform Accelerates Execution

Australian clean technology company Calix Limited (ASX: CXL) has released the first company newsletter of 2026. Managing Director and Chief Executive Officer Phil Hodgson said the company’s industrial decarbonisation platform technology is progressing from demonstration toward commercial execution, supported by advancing projects, growing revenues and disciplined cash management.

: “重量级一周”开启！美股科技巨头财报集中来袭业绩牵动市场神经

美股即将迎来本轮财报季中最具分量的一周。多家市值居前的科技巨头将在本周集中公布最新季度业绩，其结果被市场视为左右主要股指短期走向的关键变量。

: 【1.27】今日财经时讯及重要市场资讯

美股即将迎来本轮财报季中最具分量的一周。多家市值居前的科技巨头将在本周集中公布最新季度业绩，其结果被市场视为左右主要股指短期走向的关键变量。

: Strong China Demand Fuels Compumedics (ASX: CMP) Neuro-Imaging Growth New A$4.9m MEG Order from Beijing Normal University Lifts Total Orders to A$25m

ASX-listed medical technology company Compumedics Limited (ASX: CMP) announced on November 10 that it has secured a new A$4.9 million magnetoencephalography (MEG) system order from Beijing Normal University, lifting total contracted MEG revenues to about A$25 million. The deal strengthens the company’s leadership in Asia’s fast-growing neuro-imaging market and highlights robust demand from China’s expanding neuroscience sector.

: ImpediMed (ASX: IPD) Reports Record Q3 Performance; Commercial Momentum Builds and Shares Rebound

5 May 2025 | ACB News – Sydney，ImpediMed Limited (ASX: IPD), a leading Australian medical technology company, has reported record results for the third quarter of FY2025, ended 31 March. Key financial metrics reached new highs as the company continues to scale deployment of its SOZO® digital health platform in the U.S.

: A new platform suggests a new dimension of China's development

At a time when the global economic structure is undergoing profound adjustments and technological changes are accelerating, China is breaking through with a higher level of institutional opening.

: Meta自研芯片浮出水面据称已进入小规模部署阶段

据媒体报道，两位消息人士透露，美国科技巨头Meta Platforms正在测试其首款用于训练人工智能系统的自研芯片。

免责声明：本网站信息仅供一般参考，不构成投资或财务建议。虽力求准确与完整，但不保证信息的准确性、完整性或时效性。投资有风险，决策前请咨询专业独立顾问。使用本网站即视为接受本免责声明。